RxDoctor Payments Data

Luis Lopez, MD

Family Medicine · Phoenix, AZNPI 1821148917

Payments from drug & device makers

$4,376in general payments, 2019–2025

Across 193 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$589
  • Sanofi-aventis U.S. LLC$552
  • AbbVie$388
  • AstraZeneca$310
  • GSK$259
  • Abbott$258
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,358100%
  • Gifts$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,376 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$29,623
Medicare patients
49
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$49,219
JardianceEmpagliflozin31$44,411
FarxigaDapagliflozin Propanediol23$29,435
JanuviaSitagliptin Phosphate16$25,855
Soliqua 100-33Insulin Glargine/Lixisenatide16$23,516
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$22,920
Tresiba Flextouch U-100Insulin Degludec18$16,173
LantusInsulin Glargine,hum.Rec.Anlog34$6,985
Breo ElliptaFluticasone/Vilanterol12$5,144
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,739
Atorvastatin Calcium468$4,024
Gabapentin136$2,443
Metformin Hcl353$2,136
Wixela InhubFluticasone Propion/Salmeterol20$1,875
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip37$1,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$92$49,21940 claims
Boehringer IngelheimJardiance$589$44,41131 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$552$30,50050 claims
AstraZenecaFarxiga$310$29,43523 claims
GSKTrelegy Ellipta, Breo Ellipta$259$28,06426 claims
MerckJanuvia$83$25,85516 claims
Lilly USA, LLCHumulin N$254$1,34813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →